The Russian government excluded two pharmaceutical enterprises from its forecast plan for privatization of federal property in 2017-2019.
As indicated, in order to establish a large domestic research and production entity in the Russian pharmaceutical market, the Moscow Endocrine Plant, a federal state unitary enterprise, will merge with the State Plant of Medicinal Products and State Chemical and Pharmaceutical Plant, the federal state unitary enterprises. This will allow to consolidate their production capacity. The plants are primarily involved in manufacturing the narcotic and psychotropic medicinal products.
In view of this, the government order excluded the State Plant of Medicinal Products and State Chemical and Pharmaceutical Plant from the forecast plan (program) of privatization of federal property and the main areas of privatization of federal property in 2017-2019.
The purpose of consolidating the assets of these enterprises is to improve their competitiveness, optimize control over the circulation of narcotic drugs and psychotropic substances, and increase the share of Russian-made pharmaceutical products in the market.